<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721173</url>
  </required_header>
  <id_info>
    <org_study_id>T/IM -NF/Derma/15/28</org_study_id>
    <nct_id>NCT02721173</nct_id>
  </id_info>
  <brief_title>Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris</brief_title>
  <official_title>Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination therapy of retinoid and clindamycin for acne is preferred because it targets
      multiple areas of acne pathogenesis that could not be accomplished with monotherapy, thereby
      improving outcome. Literature review reveals that till date there is no published comparative
      study assessing safety and efficacy of tazarotene plus clindamycin and adapalene plus
      clindamycin. So the present study has been designed to compare these two combination therapy
      in acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne vulgaris is one of the most common disorders treated by dermatologists. The pathogenesis
      of acne is multifactorial. Critical components include abnormal follicular keratinocyte
      desquamation leading to the formation of a follicular plug (microcomedo), increase of sebum
      production in pilosebaceous unit, colonization by Propionibacterium acnes, and inflammation.
      Topical retinoids, which target comedogenesis and have anti-inflammatory activity, are
      recommended as first-line therapy for both inflammatory and non-inflammatory acne. The
      adjunctive use of anti-acne agents like clindamycin by its complementary mechanism of action
      can help to enhance the efficacy of topical retinoid therapy still further.

      Tazarotene is a synthetic retinoid and a prodrug that is converted by the skin to its active
      form, tazarotenic acid. The active form binds to retinoic acid receptors (RARs) and regulates
      gene transcription and helps to normalize the abnormal keratinization in the follicular
      infundibulum, this in turn changes the microenvironment of the follicle and thereby reduce
      the proliferation of Propionibacterium acnes. Adapalene is a synthetic naphthoic acid
      derivative with retinoid activity. Adapalene also acts through RARs and modulates cellular
      keratinization and inflammatory process. Clindamycin is bactericidal to Propionibacterium
      acnes. Due to the inhibition of P. acnes the free fatty acid levels in the pilosebaceous unit
      of skin is also reduced. Clindamycin phosphate applied topically penetrates to a very great
      extent to open comedones and thus produces a high percentage of sterile comedones.

      The combination therapy of retinoid and clindamycin for acne is preferred because it targets
      multiple areas of acne pathogenesis that could not be accomplished with monotherapy, thereby
      improving outcome. Literature review reveals that till date there is no published comparative
      study assessing safety and efficacy of tazarotene plus clindamycin and adapalene plus
      clindamycin. So the present study has been designed to compare these two combination therapy
      in acne vulgaris.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of facial acne lesions</measure>
    <time_frame>Change from baseline over 4 weeks</time_frame>
    <description>Total number of facial acne lesions (inflammatory and non-inflammatory) will be counted</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of acne</measure>
    <time_frame>Change from baseline over 4 weeks</time_frame>
    <description>Severity of acne will be assessed by Acne global severity scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of acne</measure>
    <time_frame>Change from baseline over 4 weeks</time_frame>
    <description>Severity of acne will be assessed by Investigator's static global assessment (ISGA) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Change from baseline over 4 weeks</time_frame>
    <description>Quality of life will be assessed by Acne-specific quality of life questionnaire (Acne-QoL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Tazarotene group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adapalene group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene 0.1% gel plus clindamycin 1% gel</intervention_name>
    <description>Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.</description>
    <arm_group_label>Tazarotene group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene 0.1% gel plus clindamycin 1% gel</intervention_name>
    <description>Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.</description>
    <arm_group_label>Adapalene group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with the diagnosis of facial acne vulgaris having comedones, papules,
             pustules (≤5), or nodules (≤2) or Investigator's static global assessment score ≤4

          -  Treatment naïve patients or patients who had not taken topical anti-acne medications
             in last 14 days, systemic antibiotics in last 30 days, oral retinoids in last 12
             months

        Exclusion Criteria:

          -  Very severe acne vulgaris (Investigator's static global assessment score &gt;4)

          -  Any skin disorder that might interfere with the diagnosis or evaluation of acne
             vulgaris

          -  Known hypersensitivity to retinoids and clindamycin

          -  Any uncontrolled systemic disease or any cosmetic or surgical procedures complementary
             to the treatment of acne in the preceding 15 days

          -  Patients who were on oral contraceptive pills in last 12 weeks

          -  Pregnant and nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DEBASISH HOTA, DM</last_name>
    <role>Study Director</role>
    <affiliation>AIIMS, Bhubaneswar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIIMS, Bhubaneswar</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Millikan LE. The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol. 2003;4(2):75-80. Review.</citation>
    <PMID>12553848</PMID>
  </results_reference>
  <results_reference>
    <citation>Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003 Jul;121(1):20-7.</citation>
    <PMID>12839559</PMID>
  </results_reference>
  <results_reference>
    <citation>Do TT, Zarkhin S, Orringer JS, Nemeth S, Hamilton T, Sachs D, Voorhees JJ, Kang S. Computer-assisted alignment and tracking of acne lesions indicate that most inflammatory lesions arise from comedones and de novo. J Am Acad Dermatol. 2008 Apr;58(4):603-8. doi: 10.1016/j.jaad.2007.12.024. Epub 2008 Feb 4.</citation>
    <PMID>18249468</PMID>
  </results_reference>
  <results_reference>
    <citation>Talpur R, Cox K, Duvic M. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009 Feb;5(2):195-210. Review.</citation>
    <PMID>20213916</PMID>
  </results_reference>
  <results_reference>
    <citation>Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J Jr; Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50. doi: 10.1016/j.jaad.2009.01.019. Review.</citation>
    <PMID>19376456</PMID>
  </results_reference>
  <results_reference>
    <citation>Draelos ZD, Tanghetti EA; Tazarotene Combination Leads to Efficacious Acne Results (CLEAR) Trial Study Group. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis. 2002 Feb;69(2 Suppl):20-9.</citation>
    <PMID>12095065</PMID>
  </results_reference>
  <results_reference>
    <citation>Piskin S, Uzunali E. A review of the use of adapalene for the treatment of acne vulgaris. Ther Clin Risk Manag. 2007 Aug;3(4):621-4.</citation>
    <PMID>18472984</PMID>
  </results_reference>
  <results_reference>
    <citation>Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013 Apr;12(4):438-46.</citation>
    <PMID>23652892</PMID>
  </results_reference>
  <results_reference>
    <citation>Adityan B, Kumari R, Thappa DM. Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol. 2009 May-Jun;75(3):323-6. doi: 10.4103/0378-6323.51258. Review.</citation>
    <PMID>19439902</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne -- assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001 Jul;26(5):380-5.</citation>
    <PMID>11488820</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>Chandra Sekhar Sirka</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Tazarotene</keyword>
  <keyword>Adapalene</keyword>
  <keyword>Clindamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

